NewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 5.6% – Time to Sell?

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) were down 5.6% on Monday . The company traded as low as $30.06 and last traded at $29.9130. Approximately 698,804 shares changed hands during mid-day trading, a decline of 31% from the average daily volume of 1,019,825 shares. The stock had previously closed at $31.68.

Analyst Ratings Changes

Several brokerages recently weighed in on NAMS. Royal Bank Of Canada upped their target price on shares of NewAmsterdam Pharma from $47.00 to $51.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 30th. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.00.

NewAmsterdam Pharma Stock Performance

The firm has a market capitalization of $3.50 billion, a PE ratio of -16.72 and a beta of 0.08. The company’s 50-day moving average price is $33.50 and its 200-day moving average price is $33.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The business had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. As a group, analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current year.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 40,000 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $30.20, for a total transaction of $1,208,000.00. Following the sale, the chief accounting officer owned 24,353 shares of the company’s stock, valued at approximately $735,460.60. This trade represents a 62.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 12.74% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Swedbank AB purchased a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $3,189,000. Legato Capital Management LLC raised its stake in shares of NewAmsterdam Pharma by 258.7% during the fourth quarter. Legato Capital Management LLC now owns 83,833 shares of the company’s stock worth $2,941,000 after purchasing an additional 60,463 shares during the last quarter. UBS Group AG lifted its holdings in shares of NewAmsterdam Pharma by 17.0% during the fourth quarter. UBS Group AG now owns 899,442 shares of the company’s stock worth $31,552,000 after purchasing an additional 130,922 shares during the period. JTC Employer Solutions Trustee Ltd acquired a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth $2,649,000. Finally, Aberdeen Group plc grew its position in NewAmsterdam Pharma by 10.2% in the 4th quarter. Aberdeen Group plc now owns 729,484 shares of the company’s stock valued at $25,590,000 after buying an additional 67,538 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.